TO · HBP.TO
Helix BioPharma Corp.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Richmond Hill, ON L4B 3J9
- Website
- helixbiopharma.com
Price at previous close
$1.63
Market cap 125.26M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
Valuation history
Annual price overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $9.20 | $31.73 | $0.44 | $0.00 | $0.00 |
| 2012 | $3.50 | $18.75 | $0.00 | $0.00 | $0.00 |
| 2013 | $6.40 | $60.64 | |||
| 2014 | $8.75 | ||||
| 2015 | $11.00 | ||||
| 2016 | $8.65 | ||||
| 2017 | $4.50 | ||||
| 2018 | $3.35 | ||||
| 2019 | $6.00 | ||||
| 2020 | $1.85 | ||||
| 2021 | $2.65 | ||||
| 2022 | $1.10 | ||||
| 2023 | $1.05 | ||||
| 2024 | $1.24 | ||||
| 2025 |
About Helix BioPharma Corp.
Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy to treat multiple myeloma, as well as a license agreements with Xisle Pharma Ventures Trust and National Research of Council Canada. The company is headquartered in Richmond Hill, Canada.
- CEO
- Thomas Mehrling
- Employees
- 7
- Beta
- -0.31
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $1.63) − 1 = — (DCF, example).